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Abstract
Background: Prompt and effective case detection and treatment are vital components of the malaria case management 
strategy as malaria-endemic countries implement the testing, treating and tracking policy. The implementation of this 
policy in public and formal private sectors continue to receive great attention while the informal private retail sector 
(mostly the patent and propriety medicine vendors [PPMVs]) where about 60% of patients with fever in Nigeria seek 
treatment is yet to be fully integrated. The PPMVs sell artemisinin combination therapies (ACTs) without prior testing 
and are highly patronized. Without prior testing, malaria is likely to be over-treated.  The need to expand access to 
diagnosis in the huge informal private health sector among PPMVs is currently being explored to ensure that clients that 
patronize retail drug stores are tested before sales of ACTs. 
Methods: A cross-sectional multistage study was conducted among 1279 adult clients, 20 years and above, who purchased 
malaria medicines from 119 selected PPMVs in five administrative areas (States) of Nigeria, namely: Adamawa, Cross 
River, Enugu, Lagos and Kaduna, as well as the Federal Capital Territory, Abuja. Exit interviews using a standard case 
report questionnaire was conducted after the purchase of the antimalarial medicine and thick/thin blood smears from 
the clients’ finger-prick were prepared to confirm malaria by expert microscopy. 
Results: Of the 1279 clients who purchased malaria medicines from the PPMV outlets, 107 (8.4%) were confirmed to 
have malaria parasites. The malaria prevalence in the various study areas ranged from 3.5% to 16%. A high proportion of 
clients in the various study sites who had no need for malaria medicines (84%-96.5%) purchased and used antimalarial 
medicines from the PPMVs. This indicated a high level of over-treatment and misuse of antimalarials. Common 
symptoms that are widely used as indicators for malaria such as, fever, headache, and tiredness were not significantly 
associated with malaria. Nausea/vomiting, poor appetite, chills, bitter taste in the mouth and dark urine were symptoms 
that were significantly associated with malaria among the adult clients (P < .05) but not fever (P = .06).
 Conclusion: Misuse of ACTs following overtreatment of malaria based on clinical diagnosis occurs when suspected cases 
of malaria are not prior confirmed with a test. Non-testing before sales of malaria medicines by PPMVs will perpetuate 
ACT misuse with the patients not benefiting due to poor treatment outcomes, waste of medicines and financial loss from 
out-of-pocket payment for unneeded medicines. 
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Background
Malaria in Nigeria is estimated to be responsible for 60% of 
outpatient visits to health facilities, 30% of childhood deaths, 
25% of death in children less than one year of age and 11% 
of maternal deaths.1 The 60% report of malaria in outpatient 
visitation was largely due to presumptive clinical diagnosis. 
However, with current massive deployment of malaria control 
measures such as the widespread use of long lasting insecticide 
treated nets (LLINs), use of sulphadoxine pyremithamine as 
intermittent preventive treatment of malaria in pregnancy 
(IPTp), effective malaria case management with artemisinin 
combination therapies (ACTs), indoor residual spraying 
among others, the epidemiology of malaria in Nigeria appears 
to be changing with concomitant reduction in malaria rates 
among children presenting in health facilities.2 
In 2009, the World Health Organization (WHO) 
recommended parasitological confirmation for all suspected 
cases of malaria before treatment.3 This recommendation 
was immediately implemented by the National Malaria 
Elimination Programme (NMEP) of the Federal Ministry of 
Health of Nigeria with the subsequent activation of the Malaria 
Diagnosis and Treatment Policy1 and the Malaria Diagnosis 
and Treatment Guideline.4 This policy is more operational in 
public health sector facilities and some formal private health 
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Implications for policy makers
• Policy permitting patent and propriety medicine vendors (PPMVs) to perform parasitological testing with rapid diagnostic tests (RDTs) before 
sales of antimalarial medicines will ensure an all-inclusive public and private health sectors’ implementation of the testing, treatment and 
tracking policy.
• Parasitological confirmation of malaria by PPMVs who are ubiquitous and attend to a majority of persons with fever will reduce the misuse of 
antimalarial medicines and promote appropriate management of non-malarial fevers.
• Malaria testing with RDTs by PPMVs through collaborative partnerships will promote effective malaria case management and expand access 
to universal malaria testing.
• The development of a framework that fully integrates PPMVs in malaria case management through regulation and registration, capacity 
building, monitoring and supervision, will expand access to effective malaria case management. 
Implications for the public
The symptoms of malaria are non-specific as it is similar to symptoms of a number of infections and other illness that are life threatening. Therefore, 
it is imperative for clients with malaria-like symptoms to first confirm if they had malaria or not so that their condition could be properly managed 
and not assume that artemisinin combination therapies (ACTs) would be useful when other non-malarial medicines could have been dispensed. This 
assumption could be fatal due to delay in receiving appropriate treatment. Thus, the performance of quality assured rapid diagnostic tests (RDTs) 
by patent and propriety medicine vendors (PPMVs) will reduce mortality, morbidity of other non-malarial febrile illnesses, and on the long run, the 
cost of malaria management. Consequently, it is critical that persons or clients with suspected symptoms of malaria be tested or should demand for 
prior testing before the purchase and use of ACTs. 
Key Messages 
facilities. The goal of effective case management is firstly to 
reduce morbidity and mortality by ensuring rapid, complete 
cure of Plasmodium infection, thus preventing the progression 
of uncomplicated malaria to severe and potentially fatal 
disease, as well as preventing chronic infection that leads to 
malaria-related anaemia; secondly, to curtail the transmission 
of malaria by reducing the human parasite reservoir; and 
thirdly to prevent the emergence and spread of resistance 
to antimalarial medicines. Artemisinin resistance has been 
reported in four countries in the South East Asia region, 
and the sustained potency of ACTs is a concern to the global 
community.3
In the private health sector, parasite-based diagnosis of malaria 
is infrequently done especially in the informal private retail 
sector that is dominated by the patent and propriety medicine 
vendors (PPMVs). Consequently, malaria medicines are sold 
and used without parasitological confirmation. This misuse 
of the ACTs could trigger resistance of the malaria parasites to 
these medicines, negate the need for investigating the actual 
cause of fever and importantly gloss over life-threatening 
diseases that could become fatal. Overall, the goal of 
providing effective case management of malaria, expanding 
access to parasitological testing and the attainment of national 
and global targets could be threatened. Evidence of malaria 
overdiagnosis and over-treatment has been reported in 
Nigeria,2 Tanzania,5,6 Afghanistan,7 and Ghana.8 
ACTs are sold over-the-counter in registered Pharmacies 
and by PPMVs in Nigeria and it is easy for persons with no 
malaria confirmatory diagnosis in public health facilities to 
purchase these medicines if not convinced about the outcome 
of the test. In addition, about 60% of persons with fever in 
Nigeria are first seen by the PPMVs.9 Thus, the private retail 
sector is an important platform to provide parasitological 
confirmation of malaria. The private retail sector that sells 
medicines is in different categories namely: (a) Community 
Pharmacy that is managed by Pharmacists and Licensed by 
the Regulatory Agency, Pharmaceutical Council of Nigeria 
(PCN); (b) registered PPMVs who are not pharmacists but 
are registered by PCN to sell over-the-counter medicines 
only, and (c) Unregistered PPMVs. The registered medicine 
retailers have been used as platforms to expand access to 
care given their ubiquitous nature with capacity building 
programmes provided for them by several organizations 
on different diseases. They have also been trained to report 
adverse drug events through their participation in the 
National Pharmacovigilance programme and antimalarial 
subsidy programme such as the affordable medicines facility 
for malaria (AMFm).9
To ensure effective case management of malaria with ACTs in 
all settings, it is imperative that parasitological confirmation 
of malaria be introduced at the point where malaria medicines 
are sold or dispensed. This is major challenge in African and 
Asian countries. The feasibility of introducing malaria rapid 
diagnostic tests (RDTs) to medicine retailers in the informal 
private sector have been severally described in some African 
and Asian countries.10-15 The outcome of these showed that 
malaria RDTs are easy to perform by medicine retailers with 
great potentials of expanding access to diagnosis in line with 
the diagnosis and treatment policy requirement. Studies on 
malaria parasitaemia among clients that patronized medicine 
retailers in Tanzania showed that a considerable number of 
these clients would not need antimalarial medicines.16,17 In 
Nigeria, current regulatory policy on the PPMVs does not 
permit them to perform minimally invasive procedures. 
This includes the performance of malaria RDT that requires 
fingerpicking to collect blood. Data on ACT misuse emanating 
from the prevalence of malaria among persons suspected to 
have malaria who purchased antimalarials from the PPMVs 
is needed to provide evidence for a policy change that will 
institute parasitological confirmation of malaria at settings 
where antimalarial medicines are sold. This study reports 
ACT misuse among adult clients suspected to have malaria 
that purchased malaria medicines from PPMVs in Nigeria.
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Methods
Study Sites and Population
This study was conducted in retail outlets of PPMVs in five 
states spread across five geopolitical zones of the country 
including the Federal Capital Territory, Abuja. These are: 
Adamawa (North-East zone); Cross River (South-South), 
Enugu (South-East), Lagos (South-West), Kaduna (North-
West) and the Federal Capital Territory of Abuja. Nigeria, 
with an estimated population of 180 million people, consists 
of six geopolitical zones with 36 states and the Federal Capital 
Territory (FCT), Abuja. The study sites were unevenly 
distributed in five geopolitical zones namely: North-Central, 
North-West, South-South, South-East and South West; and 
are spread across various ecological zones (Figure 1). The 
population studied were made of adult male and females, 20 
years and above who gave consent to participate. The study 
was conducted between November and December 2012 
during the dry season when transmission of malaria is low. 
Study Design
A cross-sectional, multi-stage purposive sampling was used 
to select the states and the PPMVs that participated in the 
study while all eligible clients that qualified for the study 
were randomly selected based on odd number presentation. 
Essentially, a client was skipped after a previous enrollment 
until the third eligible client arrived so as to remove bias in 
the client selection. This study was conducted within a larger 
study on the feasibility of conducting malaria diagnosis in 
private sector retail facilities. 
The selection of the PPMVs was done in three stages: Stage 
1: This involved the selection of one state from each of the 
six geopolitical zones. These states represented different 
geographic and linguistic-ethnic regions of the country, 
malaria zones within the country and preponderance of 
PPMVs. Stage 2: Rural and urban local government areas 
(LGAs) were selected in each of the states. Stage 3: The PPMVs 
were selected from a list of medicine stores partnering with the 
Global Fund Malaria Project implemented in Nigeria by The 
Society for Family Health. The criteria for selecting PPMVs 
study included availability in the area most of the time, 
acceptability by the community, educational level (minimum 
of secondary school education), and consent to participate. 
About 20 registered PPMVs were selected from each of the 
selected states through a computer-generated randomization 
of registered PPMVs from which numbers representing 
facility names were selected. These outlets were grouped into 
clusters of 6 per state. All the outlets used for the study were 
mapped using the global positioning system (GPS) [Garmin 
Corporation]. Laboratory personnel were trained on how to 
prepare thick and thin blood smears for malaria microscopy. 
Research Assistants who conducted exit interviews with 
clients who purchased an ACT at each study point were also 
trained. The research assistants were health workers with 
clinical training and have experience in managing patients at 
the lower level of care. 
The minimum sample size required for the exit interview 
component of the study was calculated by anticipating a 15% 
level of change, assuming that the current level of quality 
provided is 25%. With a design effect fixed at 1.5, level of 
significance at 5%, power of test at 80% and adjusting for a 
10% non-response, a minimum sample of 179 per state was 
achieved. This was rounded up to a total of 200 for each 
state representing a geopolitical zone. Therefore, in the six 
selected states it was estimated that a total of 1200 clients who 
purchased ACTs from the various PPMV outlets would be 
interviewed and malaria parasite test performed. 
Sample and Data Collection
The PPMVs were grouped in clusters with an interviewer and 
laboratory scientist assigned to each group. PPMVs alerted 
the laboratory scientist/research assistants who were within 
the vicinity when a client visited the outlet seeking malaria 
treatment. A minimum of 10 clients, who visited each of the 
PPMVs, purchased ACT for the treatment for malaria and 
who gave consent was enrolled for the study. The inclusion 
criteria used in enrolling the clients that participated were: 
adults, 20 years and above; patients requiring malaria 
treatment (ACTs) and written consent. The exclusion criteria 
were: non-adults, less than 20 years of age; refusal to consent; 
clients not buying medicine for use; and clients with severe 
illness. The exit interview was done using a questionnaire that 
captured information on the age, gender, educational level, 
economic status, presenting symptoms, etc.
 
Malaria Microscopy
Thin and thick blood films were prepared on the same slide 
by trained laboratory scientists. The slides were made in 
duplicates for each client and labeled appropriately. Thin 
film was fixed by dipping the thin film end of the slide in a 
beaker containing absolute methanol for 1-2 seconds and 
air-dried. All prepared slides were packaged in a slide box 
and immediately sent to the ANDI Centre of Excellence in 
Malaria Diagnosis, College of Medicine of the University 
of Lagos, Lagos, Nigeria, where they were stained with 3% 
Giemsa stain at pH 7.2. Two WHO-certified microscopists 
read the Giemsa-stained slides. Discordant readings in 
parasite detection and parasite densities were resolved before 
the final result was taken. A total of 200 oil immersion fields 
Figure 1. Study Sites in Five Geopolitical Zones Where Clients 
That Purchased ACTs Were Tested in Nigeria. Abbreviation: ACts, 
artemisinin combination therapies.
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(OIFs) were read before a slide was declared negative. The 
mean parasite densities obtained by two microscopists was 
used to determine the parasite density per client provided 
the percentage discrepancy of the two readings was less than 
20%. The absolute parasite density (parasite per microliter of 
blood) was calculated by multiplying the number of parasites 
counted with an estimated 8000 leucocytes and divided by 
the relative leucocytes counted. In all cases, a third WHO-
certified microscopist served as the tiebreaker.
Feedback on the outcome of the malaria microscopy test was 
shared with the PPMVs and the clients that were tested.
Data Analysis
The data obtained from the study was entered and verified 
using the data management software, CSPro 2.6 and 
subsequently imported into SPSS (version 18) for statistical 
analysis. Test for association was done using the Pearson chi-
square test at .05 significant levels. 
Results 
Characteristics of Registered Drug Shop Owners (PPMVs)
A total of 119 PPMVs from the 130 that were trained 
participated in the study from the six states selected from 
the six geopolitical zones of the country. These included 21 
PPMVs from Lagos state, Enugu state (19), Cross River (20), 
FCT (16), Adamawa state (25), and Kaduna state (18). 
Characteristics of the Clients
The 1279 respondents, 20 years and above, who sought 
treatment for their illness from the PPMV outlets were: 188 
from Enugu State, Cross River (229), FCT (213), Kaduna 
(256), Adamawa (188), and Lagos State (205). The median 
age of respondents was 32 years. The proportion of males in 
the population was 55% while females were 45%. Sixty-two 
percent of the respondents were married. The educational 
level of respondents who participated in the survey showed 
that 43% had attained a secondary level of education, one in 
four (25%) of the respondents had attained a higher level of 
education (Table 1).
Symptoms Presented by the Tested Clients at the Shops of 
PPMVs
The visit to the PPMVs in most cases was after 48 hours of 
initial symptoms (72%) (Figure 2). The reported symptoms 
by most of the respondents can be associated with, but may 
not be specific to malaria. Fever (63%), headache (81%), joint 
pains (57%), tiredness (40%), bitter taste (32%), and poor 
appetite (28%) were the most common symptoms reported 
by clients that sought for treatment from the PPMVs (Figure 
2). Most of the clients sought treatment after two days of 
experiencing symptoms.
Prevalence of Malaria Among Clients that Visited and 
Purchased Malaria Medicines From PPMVs
In general, blood smear results by microscopy across the 
study sites showed that of the 1279 clients tested, 107 (8.4%) 
were confirmed to have malaria. The confirmed malaria rates 
in the states were: Enugu, 20 (10.6%), Cross River 8 (3.5%), 
FCT 16 (7.5%), Kaduna 15 (6%), Adamawa 30 (16%), and 
Lagos 18 (8.8%). The distribution of Plasmodium species in 
this study was: Plasmodium falciparium (99%), P. malariae 
(0.1%) while the remaining were mixed infections with Pf (P. 
malariae and P. ovale). Further more, majority of the parasite 
stages encountered were trophozoites (91%) and other stages 
were mix of both trophozoite and gametocytes. 
Malaria Symptoms by Clients at Presentation at Medicine 
Retail Shops
In this study, majority of the clients visited PPMVs after two 
days of having malaria-like symptoms. Those that purchased 
antimalarial medicines at the first day of having symptoms 
were lower compared to those that visited the PPMVs and 
purchased medicines a day after symptoms were observed 
(Figure 2). The most common symptoms of the client at 
presentation at PPMVs were: Headache (81%), fever (63%), 
joint pains (57%), and tiredness (40%) while the least was 
nausea (11%) (Figure 2). 
Symptoms of Clients With Confirmed Malaria by Microscopy 
None of the most common symptoms at presentation by 
the clients had significant correlation with malaria by 
microscopy. Headache, fever, joint pains and tiredness were 
not significantly associated with malaria among clients, 20 
years and above that were studied. However, nausea/vomiting, 
poor appetite, chills, bitter taste in the mouth and dark urine 
Table 1. Characteristics of Clients that Purchased Antimalarial Medicines 
From the PPMVs
Description, n = 1279 No. (%)
State
Adamawa 186 (14.8)
Cross River 228 (18.2)
Enugu 180 (14.3)
FCT 210 (16.7)
Kaduna 248 (19.7)
Lagos 204 (16.2)
Gender 
Male 685 (54.5)
Female 570 (45.4)
Marital status
Married 769 (62.2)
Single 412 (33.3)
Divorced 43 (3.5)
Age 
20–24 years 178 (13.9)
25–29 years 216 (16.9)
30–34 years 234 (18.2)
35–39 years 134 (10.5)
40–44 years 125 (9.80)
45–49 years 185 (14.5)
50 years and above 207 (16.2)
Education 
None 149 (11.6)
Quranic only    51 (4.0)
Primary 225 (17.6)
Secondary 546 (42.7)
Higher 308 (24.1)
Abbreviations: PPMVs, patent and propriety medicine vendors; FCT, Federal 
Capital Territory.
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were significantly associated with malaria among the clients 
(P < .05) but not fever (P = .056) (Table 2). Of the 796 clients 
that had fever/symptoms of fever, 76 (9.5%) had malaria 
parasites while 720 (90.5%) were aparasitaemic (Table 2).
Discussion
One of the control strategies for malaria is effective case 
management that requires early diagnosis and prompt 
treatment with ACTs. Current malaria case management 
recommendation requires prior parasitological confirmation 
of all suspected cases of malaria before treatment by either 
microscopy or malaria RDTs. The need for prior testing of 
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Figure 2. Symptoms of Clients that Purchased ACTs From PPMVs. Abbreviations: PPMVs, patent and propriety medicine vendors; ACTs, 
artemisinin combination therapies.
Table 2. Symptoms of Clients Who Purchased ACTs in Retail Medicine 
Shops and Malaria
Symptoms
Microscopy 
Positive
No. (%)
Microscopy Negative
No. (%)
P Value
(n = 107) (n = 1167)
Fever 76 (71.0) 720 (61.7) .056
Headache 87 (81.3) 950 (81.4) .980
Dizziness 25 (23.4) 286 (24.5) .792
Sweating 25 (23.4) 232 (19.9) .390
Nausea/vomiting 19 (17.8) 119 (10.2) .016*
Poor appetite 44 (41.1) 314 (26.9) .002*
Abdominal pain 20 (18.7) 180 (15.4) .374
Diarrhoea 6 (5.6) 38 (3.3) .202
Shortness of breath 6 (5.6) 59 (5.1) .804
Congestion 4 (3.7) 31 (2.7) .512
Dry cough 12 (11.2) 166 (14.2) .390
Convulsion 2 (1.9) 9 (0.8) .240
Joint pain 67 (62.6) 662 (56.7) .239
Chills 35 (32.7) 211 (18.1) .000*
Yellow eyes 9 (8.4) 71 (6.1) .342
Tiredness 45 (42.1) 474 (40.6) .772
Bitter taste in the 
mouth
45 (42.1) 365 (31.3) .022*
Dark urine 28 (26.2) 199 (17.1) .018*
Abbreviation: ACTs, artemisinin combination therapies.
suspected malaria cases is critical given the poor specificity 
of clinical criteria in the diagnosis of malaria in light of 
several aetiologies of fever. The implementation of this 
recommendation in medicine retailer’s outlets is just 
emerging and the evidence on malaria confirmed rates in 
the informal private health sector that is controlled by the 
PPMVs is scarce. The changing epidemiology of malaria from 
high endemicity to hypoendemicity implies that widespread 
presumptive treatment may lead to over-use of antimalarial 
medicines given reduced malaria rates. This study provides 
evidence for policy to curb the irrational use of ACTs among 
clients who seek treatment from PPMVs without prior 
parasitological confirmation of malaria before treatment or 
sales of antimalarial medicines. 
Malaria medicines are directly requested by clients from 
PPMVs who believed they had malaria and in most cases, 
the PPMVs would recommend antimalarial medicines 
following complaints from their clients. The request for ACTs 
by clients or prescription by PPMVs was done based on the 
widespread belief that fever, in addition to other symptoms, 
such as headache and tiredness, for example are indicators of 
malaria. The confirmation of malaria requires the detection 
of Plasmodium by microscopy or the appropriate Plasmodium 
antigen by malaria RDTs in patients with presenting symptoms. 
Thus, the non-establishment of Plasmodium parasitaemia or 
antigenemia by malaria RDTs with concomitant use of ACTs 
is tantamount to ACT misuse. The 8.4% prevalence of Malaria 
among adult clients confirmed by microscopy provides the 
first evidence in Nigeria and showed a high level of misuse 
of ACTs. We have shown in this study that fever was not 
significantly associated with malaria; yet it was an indicator to 
treat for malaria. It was one of the symptoms that accounted 
for 90.5% misuse of ACTs among the adult clients in our study 
population. 
The consequences of presumptive use of ACTs among the 
studied group could delay early intervention in non-malarial 
febrile illness, as patients may not receive the appropriate 
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treatment for their condition. Similar observations have 
been reported in some African countries. The prevalence of 
malaria parasitaemia among clients seeking treatment for 
fever or malaria at drug stores in rural Tanzania showed that 
63.8% of them were clinically diagnosed for malaria while 
malaria blood film confirmation was 24.2%.15 Another report 
that underscored the need for prior testing before sales of 
antimalarial medicines from two regions of Tanzania among 
777 clients from 73 drug shops showed that parasitologically-
confirmed malaria was 12%.16
Furthermore, a systematic review of reports from 16 African 
countries showed a considerable reduction in the proportion 
of fevers associated with Plasmodium falciparum parasitaemia 
and this justified the policy change from presumptive 
antimalarial treatment of children with fever to laboratory 
diagnosis before treatment.17 
There is an urgent need to expand access to parasitological 
confirmation of malaria18 in the informal private retail sector 
in countries where they provide service to large number 
of people. Already, a number of published studies have 
demonstrated feasibility of using malaria RDTs in drug 
shops.9-14 Ikwuobe et al19 highlighted possible over-treatment 
of malaria with a reported malaria prevalence of 13.6% in 
Gwagwalada, Nigeria, using malaria RDTs among patients 
that visited community pharmacies. Substantial symptoms’ 
overlap has also been reported between malaria and other 
common illnesses caused by viral and bacterial infections20 
while drastic reduction in antimalarial drug consumption are 
positive outcome of malaria confirmation before treatment as 
reported in Tanzania, Zambia, and Senegal.21-23 
Conclusion
The level of ACT misuse among adult clients suspected to 
have malaria that visited selected PPMV shops in Nigeria 
was high. Some common symptoms that are widely used 
as an indicator of malaria such as fever, headache, and 
tiredness were not significantly associated with confirmed 
malaria parasitaemia among the adult clients that purchased 
antimalarial medicines. Early detection and prompt 
treatment is critical for effective malaria case management. 
Consequently, to prevent the eventual fatality of patients that 
may present with other life-threatening non-malarial febrile 
conditions that could be erroneously managed as malaria, 
promotion of prompt and effective management of malaria, 
through parasitological confirmation of suspected malaria 
at the points where malaria medicines are sold or dispensed 
is imperative. A strategic framework for parasitological 
confirmation of suspected malaria cases by PPMVs should 
be developed, implemented and monitored. Access to malaria 
diagnosis will substantially reduce excessive and unnecessary 
consumption of ACTs.
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